This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Biogen Idec(BIIB - Get Report) upgraded at RBC from Sector Perform to Outperform, RBC Capital said. $75 price target. New analyst expects Tysabri to perform above consensus expectations.
Celgene(CELG - Get Report) downgraded at RBC from Outperform to Sector Perform, RBC Capital said. $55 price target. Valuation call, as the stock is already pricing in solid 2011 growth.
Chesapeake Energy(CHK - Get Report) upgraded at Canaccord from Hold to Buy, Canaccord Genuity said. $49 price target. Company is improving capital productivity and realizing higher gas prices.
Ciena(CIEN - Get Report) rated new Outperform at Wells Fargo. Company is leveraged to a multi-year optical upgrade cycle.
Celestica(CLS - Get Report) upgraded at Collins Stewart from Neutral to Buy, Collins Stewart said. $15 price target. Company is turning its business around and winning new customers.
Flextronics(FLEX) upgraded at Collins Stewart from Neutral to Buy, Collins Stewart said. $11 price target. Company can deliver double-digit growth in each of the next two years.
Fluor(FLR) upgraded at BMO from Underperform to Market Perform, BMO Capital said. $66 price target. Company has a solid balance sheet, and can absorb losses from two fixed-price contracts.
Netease.com(NTES) upgraded at Brean Murray from Hold to Buy, Brean Murray said. $54 price target. Company is seeing higher demand across the board.
Ormat Technologies(ORA) downgraded at Baird to Neutral from Outperform, Robert Baird said. $24 price target. Company lowered its guidance, because of rising costs.
Oracle(ORCL) rated new Hold at ThinkEquity. $35 price target. Stock is already pricing in solid near-term growth.
Quanta Services(PWR) downgraded at Deutsche Bank to Hold. $22 price target. Valuation call, as the stock is up 26% over the past three months.
Regeneron Pharmaceuticals(REGN) upgraded at RBC from Sector Perform to Outperform, RBC Capital said. $48 price target. Company continues to price solid clinical data.
Red Hat(RHT - Get Report) downgraded at JP Morgan from Neutral to Underweight. $32 price target. Valuation call, as the stock is already pricing in healthy free cash flow growth.